Project profile — Support to COVID-19 Therapeutics

• Africa, regional (20.00%)
• America, regional (20.00%)
• Asia, regional (20.00%)
• Oceania, regional (20.00%)
• Europe, regional (20.00%)

• Basic Health: Infectious disease control (12250) (50.00%)
• Health: COVID-19 control (12264) (50.00%)

• Gender equality (significant objective)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (not targeted)
• Youth Issues (not targeted)
• Disaster Risk Reduction(DRR) (not targeted)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• Nutrition (not targeted)
• ICT as a tool for development (not targeted)

This project aims to advance equitable and affordable access to the most promising COVID-19 treatments in lower-income countries and lower-middle-income countries (LMICs). The project supports Unitaid in securing manufacturing capacity and supply for relevant treatments, including monoclonal antibodies, novel antivirals, and medical oxygen. This project contributes to the Access to COVID-19 Tools (ACT) -– Accelerator Therapeutics Partnership objectives. Project activities include: (1) increasing access to medical oxygen; (2) improving supply security across sub-Saharan Africa through market interventions; and (3) piloting the introduction, feasibility and acceptability of innovations in at least 5 countries. This project represents additional funds provided to a pre-existing project in response to the COVID-19 pandemic. The description and expected results are the same.

The expected outcomes of the project include: (1) increased capacity of oxygen produced and delivered to low- and lower-middle income countries; (2) an expanded portfolio of fit-for-purpose new therapeutics adapted for low and middle income countries; and (3) ensured availability and affordability of therapeutics and a related package of care in low- and lower-middle income countries.

N/A

• Proactive disclosure
• Related activities: Support to COVID-19 therapeutics